StockNews.AI
SYRE
StockNews.AI
11 hrs

Spyre Therapeutics to Participate in Stifel 2025 Virtual Immunology and Inflammation Forum

1. Spyre Therapeutics to participate in Stifel Immunology Forum on September 15. 2. Fireside chat aims to showcase advancements in inflammatory bowel disease treatments. 3. Spyre's pipeline includes innovative antibodies targeting key immune pathways.

3m saved
Insight
Article

FAQ

Why Bullish?

Participation in influential forums usually raises investor interest, boosting stock confidence.

How important is it?

Investor events signal potential partnerships or advancements, impacting market performance positively.

Why Short Term?

Upcoming event likely to influence knowledge and perception of Spyre quickly.

Related Companies

VRTXABBVREGN
WALTHAM, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease (“IBD”) and other immune-mediated diseases, today announced that management will participate in a fireside chat and investor meetings at the Stifel 2025 Virtual Immunology and Inflammation Forum. Fireside details below: Event: Stifel 2025 Virtual Immunology and Inflammation ForumDate: Monday, September 15, 2025Fireside Time: 10:00 a.m. ET Live audio webcasts and replays of these events will be available on the Spyre investor events website at https://ir.spyre.com/news-events/events. About Spyre Therapeutics Spyre Therapeutics is a biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) and other immune-mediated disease products by combining best-in-class antibody engineering, dose optimization, and rational therapeutic combinations. Spyre’s pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23. For more information, visit Spyre's website at www.spyre.com. Follow Spyre Therapeutics on social media: @spyretx and LinkedIn For Investors :Eric McIntyre, VP of Finance and Investor RelationsEric.mcintyre@spyre.com

Related News